OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+11.44%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$46.1M
AUM Growth
-$1.57M
(-3.3%)
Cap. Flow
-$2.17M
Cap. Flow
% of AUM
-4.71%
Top 10 Holdings %
Top 10 Hldgs %
52.4%
Holding
52
New
2
Increased
15
Reduced
16
Closed
2
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$3.26M |
| 2 |
MEI Pharma
MEIP
|
$1.58M |
| 3 |
Exelixis
EXEL
|
$292K |
| 4 |
Incyte
INCY
|
$69.9K |
| 5 |
Alkermes
ALKS
|
$50.2K |
Top Sells
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$5.37M |
| 2 |
Nektar Therapeutics
NKTR
|
$728K |
| 3 |
Karyopharm Therapeutics
KPTI
|
$671K |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$327K |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$281K |
Sector Composition
| 1 | Healthcare | 70.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Karyopharm Therapeutics
KPTI
$61.4M
| – | – |
-3,333
| Closed | -$671K |
|
|
AVXS
52
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-2,275
| Closed | -$281K |
|